{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:07:30Z","timestamp":1779361650419,"version":"3.51.4"},"reference-count":120,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Degenerative cervical myelopathy (DCM) is the most common cause of cervical spinal cord impairment in adults. It is described as progressive, age-related spinal cord compression due to degenerative changes in the spinal column. While the mechanical pathology of DCM is well characterized, the immune system\u2019s role in the disease\u2019s neurological progression and potential as a therapeutic target remains unclear. The authors aimed to comprehensively review the available literature on immunological involvement in DCM pathogenesis. Understanding the interactions between inflammation, apoptosis, and neurodegeneration in DCM may provide insights into novel treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A systematic literature review was conducted in the PubMed database through August 1, 2024, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Papers met inclusion criteria for the review if they reported on molecular, histological, CSF, or peripheral markers of immune involvement or the immune response, causation, or relation to DCM. Systematic reviews, case reports, or animal studies were excluded. Studies were screened by two blinded authors based on relevance and synthesized to assess the immune environment in DCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 113 studies were identified, with 10 meeting the inclusion criteria. Findings revealed elevated proinflammatory cytokines in the CSF of DCM patients, including interleukin-8 and tumor necrosis factor\u2013\u03b1, as well as increased oligoclonal IgG bands and blood\u2013spinal cord barrier disruption. Histological analysis demonstrated apoptosis via Fas-mediated pathways, impaired autophagy, and increased staining for activated myeloid cells in DCM tissue compared to controls. Peripheral immune profiling indicated increased M2 macrophages and activated CD4 T cells in DCM patients. Furthermore, serum S100b postoperative values and perioperative CSF levels of neurofilament light chain and glial fibrillary acidic protein correlated significantly with clinical improvement and favorable outcomes following treatment. This review is limited by the number of eligible studies, causal interpretation and temporal bias, and lack of standardized interstudy biomarker analysis. These findings identify an immune component of DCM neurodegeneration that may influence disease severity and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>There is a significant interplay between immune responses and DCM disease progression, revealing how inflammatory mechanisms can influence clinical outcomes and treatment efficacy. Further studies are warranted to understand the immune component of DCM and pave the way for targeted immunotherapies alongside surgical decompression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2025.12.spine251122","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:39:25Z","timestamp":1779359965000},"page":"1-12","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing immune involvement in degenerative cervical myelopathy: a systematic review"],"prefix":"10.3171","author":[{"given":"Peter J.","family":"Chabot","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Winans","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua S.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas B.","family":"Dadario","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis S.","family":"CreveCoeur","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Rolfe","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison J.","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailen G.","family":"Sampath","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"issue":"6","key":"b1","series-title":"Can J Neurol Sci","first-page":"729","article-title":"Degenerative cervical myelopathy: towards a personalized approach","volume":"49","author":"Hejrati N","year":"2022","unstructured":"Hejrati N, Moghaddamjou A, Marathe N, Fehlings MG. Degenerative cervical myelopathy: towards a personalized approach. Can J Neurol Sci. 2022;49(6):729\u2013740. doi:10.1017\/cjn.2021.214"},{"issue":"2","key":"b2","series-title":"Nat Rev Neurol","first-page":"108","article-title":"Degenerative cervical myelopathy\u2014update and future directions","volume":"16","author":"Badhiwala JH","year":"2020","unstructured":"Badhiwala JH, Ahuja CS, Akbar MA,  Degenerative cervical myelopathy\u2014update and future directions. Nat Rev Neurol. 2020;16(2):108\u2013124. doi:10.1038\/s41582-019-0303-0"},{"issue":"16","key":"b3","series-title":"J Clin Med","first-page":"3626","article-title":"Degenerative cervical myelopathy: clinical presentation, assessment, and natural history","volume":"10","author":"Lannon M","year":"2021","unstructured":"Lannon M, Kachur E. Degenerative cervical myelopathy: clinical presentation, assessment, and natural history. J Clin Med. 2021;10(16):3626. doi:10.3390\/jcm10163626"},{"key":"b4","series-title":"World Neurosurg","first-page":"699","article-title":"Comparing quality of life in cervical spondylotic myelopathy with other chronic debilitating diseases using the Short Form Survey 36-Health Survey","volume":"106","author":"Oh T","year":"2017","unstructured":"Oh T, Lafage R, Lafage V,  Comparing quality of life in cervical spondylotic myelopathy with other chronic debilitating diseases using the Short Form Survey 36-Health Survey. World Neurosurg. 2017;106:699\u2013706. doi:10.1016\/j.wneu.2016.12.124"},{"issue":"5","key":"b5","series-title":"J Neurosurg Spine","first-page":"758","article-title":"Determining the time frame of maximum clinical improvement in surgical decompression for cervical spondylotic myelopathy when stratified by preoperative myelopathy severity: a cervical Quality Outcomes Database study","volume":"37","author":"Berlin C","year":"2022","unstructured":"Berlin C, Marino AC, Mummaneni PV. Determining the time frame of maximum clinical improvement in surgical decompression for cervical spondylotic myelopathy when stratified by preoperative myelopathy severity: a cervical Quality Outcomes Database study. J Neurosurg Spine. 2022;37(5):758\u2013766. doi:10.3171\/2022.5.SPINE211425"},{"issue":"4","key":"b6","series-title":"J Neurosurg Spine","first-page":"453","article-title":"What predicts the best 24-month outcomes following surgery for cervical spondylotic myelopathy? A QOD prospective registry study","volume":"40","author":"Chan AK","year":"2024","unstructured":"Chan AK, Park C, Shaffrey CI,  What predicts the best 24-month outcomes following surgery for cervical spondylotic myelopathy? A QOD prospective registry study. J Neurosurg Spine. 2024;40(4):453\u2013464. doi:10.3171\/2023.11.SPINE23222"},{"issue":"19","key":"b7","series-title":"Spine (Phila Pa 1976)","first-page":"1319","article-title":"Clinical indicators of surgical outcomes in degenerative cervical myelopathy assessed using the JOACMEQ: a prospective multicenter study","volume":"50","author":"Nagoshi N","year":"2025","unstructured":"Nagoshi N, Yamane J, Okubo T,  Clinical indicators of surgical outcomes in degenerative cervical myelopathy assessed using the JOACMEQ: a prospective multicenter study. Spine (Phila Pa 1976). 2025;50(19):1319\u20131326. doi:10.1097\/BRS.0000000000005428"},{"issue":"6","key":"b8","series-title":"Neurosurg Focus","first-page":"E5","article-title":"Which supervised machine learning algorithm can best predict achievement of minimum clinically important difference in neck pain after surgery in patients with cervical myelopathy? A QOD study","volume":"54","author":"Park C","year":"2023","unstructured":"Park C, Mummaneni PV, Gottfried ON,  Which supervised machine learning algorithm can best predict achievement of minimum clinically important difference in neck pain after surgery in patients with cervical myelopathy? A QOD study. Neurosurg Focus. 2023;54(6):E5. doi:10.3171\/2023.3.FOCUS2372"},{"issue":"1","key":"b9","series-title":"Fluids Barriers CNS","first-page":"68","article-title":"Blood-spinal cord barrier disruption in degenerative cervical myelopathy","volume":"20","author":"Kim HW","year":"2023","unstructured":"Kim HW, Yong H, Shea GKH. Blood-spinal cord barrier disruption in degenerative cervical myelopathy. Fluids Barriers CNS. 2023;20(1):68. doi:10.1186\/s12987-023-00463-y"},{"issue":"2","key":"b10","series-title":"Lancet Neurol","first-page":"98","article-title":"Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Fehlings MG","year":"2021","unstructured":"Fehlings MG, Badhiwala JH, Ahn H,  Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Neurol. 2021;20(2):98\u2013106. doi:10.1016\/S1474-4422(20)30407-5"},{"issue":"3","key":"b11","series-title":"BMJ Open","first-page":"e061294","article-title":"Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial\u2014study protocol","volume":"13","author":"Davies B","year":"2023","unstructured":"Davies B, Mowforth OD, Yordanov S,  Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial\u2014study protocol. BMJ Open. 2023;13(3):e061294. doi:10.1136\/bmjopen-2022-061294"},{"key":"b12","article-title":"Finding What Works in Health Care: Standards for Systematic Reviews.","year":"2011","unstructured":"Eden J, Levit L, Berg A, Morton S, eds.Finding What Works in Health Care: Standards for Systematic Reviews. National Academies Press (US);2011. doi:10.17226\/13059"},{"issue":"7","key":"b13","series-title":"PLoS Med","first-page":"e1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J,  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371\/journal.pmed.1000100"},{"issue":"Pt 5","key":"b14","series-title":"Brain","first-page":"1277","article-title":"Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy","volume":"134","author":"Yu WR","year":"2011","unstructured":"Yu WR, Liu T, Kiehl TR, Fehlings MG. Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy. Brain. 2011;134(Pt 5):1277\u20131292. doi:10.1093\/brain\/awr054"},{"issue":"1","key":"b15","series-title":"Sci Rep","first-page":"11873","article-title":"Evidence of impaired macroautophagy in human degenerative cervical myelopathy","volume":"12","author":"Smith SS","year":"2022","unstructured":"Smith SS, Young AMH, Davies BM, Takahashi H, Allinson KSJ, Kotter MRN. Evidence of impaired macroautophagy in human degenerative cervical myelopathy. Sci Rep. 2022;12(1):11873. doi:10.1038\/s41598-022-15158-x"},{"issue":"2","key":"b16","series-title":"Immunity","first-page":"180","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser A","year":"2009","unstructured":"Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180\u2013192. doi:10.1016\/j.immuni.2009.01.001"},{"issue":"5203","key":"b17","series-title":"Science","first-page":"1449","article-title":"The Fas death factor","volume":"267","author":"Nagata S","year":"1995","unstructured":"Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449\u20131456. doi:10.1126\/science.7533326"},{"issue":"3","key":"b18","series-title":"Cell","first-page":"355","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata S","year":"1997","unstructured":"Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355\u2013365. doi:10.1016\/s0092-8674(00)81874-7"},{"issue":"1","key":"b19","series-title":"J Cell Biol","first-page":"15","article-title":"Cell nucleus and DNA fragmentation are not required for apoptosis","volume":"127","author":"Schulze-Osthoff K","year":"1994","unstructured":"Schulze-Osthoff K, Walczak H, Dr\u00f6ge W, Krammer PH. Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol. 1994;127(1):15\u201320. doi:10.1083\/jcb.127.1.15"},{"issue":"1","key":"b20","series-title":"Sci Rep","first-page":"7389","article-title":"Blood spinal cord barrier disruption recovers in patients with degenerative cervical myelopathy after surgical decompression: a prospective cohort study","volume":"13","author":"Schmidt TP","year":"2023","unstructured":"Schmidt TP, J\u00fctten K, Bertram U,  Blood spinal cord barrier disruption recovers in patients with degenerative cervical myelopathy after surgical decompression: a prospective cohort study. Sci Rep. 2023;13(1):7389. doi:10.1038\/s41598-023-34004-2"},{"issue":"2","key":"b21","series-title":"J Spinal Disord Tech","first-page":"145","article-title":"Analysis of interleukin-8, interleukin-10, and tumor necrosis factor-alpha in the cerebrospinal fluid of patients with cervical spondylotic myelopathy","volume":"21","author":"Ito K","year":"2008","unstructured":"Ito K, Matsuyama Y, Yukawa Y, Kato F, Ishiguro N. Analysis of interleukin-8, interleukin-10, and tumor necrosis factor-alpha in the cerebrospinal fluid of patients with cervical spondylotic myelopathy. J Spinal Disord Tech. 2008;21(2):145\u2013147. doi:10.1097\/BSD.0b013e31806458b3"},{"issue":"11","key":"b22","series-title":"Spine J","first-page":"1848","article-title":"Cerebrospinal fluid biomarkers of white matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative cervical spondylotic myelopathy","volume":"22","author":"Tsitsopoulos PP","year":"2022","unstructured":"Tsitsopoulos PP, Mondello S, Holmstr\u00f6m U, Marklund N. Cerebrospinal fluid biomarkers of white matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative cervical spondylotic myelopathy. Spine J. 2022;22(11):1848\u20131856. doi:10.1016\/j.spinee.2022.06.012"},{"issue":"4","key":"b23","series-title":"Arch Neurol","first-page":"553","article-title":"Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions","volume":"57","author":"Cohen O","year":"2000","unstructured":"Cohen O, Biran I, Steiner I. Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions. Arch Neurol. 2000;57(4):553\u2013557. doi:10.1001\/archneur.57.4.553"},{"issue":"1","key":"b24","series-title":"Sci Rep","first-page":"2497","article-title":"Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy","volume":"11","author":"Blume C","year":"2021","unstructured":"Blume C, Geiger MF, M\u00fcller M,  Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy. Sci Rep. 2021;11(1):2497. doi:10.1038\/s41598-021-81766-8"},{"issue":"5 suppl","key":"b25","series-title":"J Periodontol","first-page":"456","article-title":"The role of interleukin-8 in inflammation and mechanisms of regulation","volume":"64","author":"Bickel M","year":"1993","unstructured":"Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol. 1993;64(5 suppl):456\u2013460."},{"key":"b26","series-title":"Front Immunol","first-page":"1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini V","year":"2023","unstructured":"Carlini V, Noonan DM, Abdalalem E,  The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023;14:1161067. doi:10.3389\/fimmu.2023.1161067"},{"issue":"3","key":"b27","series-title":"Microsc Res Tech","first-page":"184","article-title":"TNF\u03b1 and the TNF receptor superfamily: structure-function relationship(s)","volume":"50","author":"Idriss HT","year":"2000","unstructured":"Idriss HT, Naismith JH. TNF\u03b1 and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50(3):184\u2013195. doi:10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H"},{"key":"b28","series-title":"J Neuroinflammation","first-page":"150","article-title":"Neutrophil contribution to spinal cord injury and repair","volume":"11","author":"Neirinckx V","year":"2014","unstructured":"Neirinckx V, Coste C, Franzen R, Gothot A, Rogister B, Wislet S. Neutrophil contribution to spinal cord injury and repair. J Neuroinflammation. 2014;11:150. doi:10.1186\/s12974-014-0150-2"},{"key":"b29","series-title":"Brain Behav Immun Health","first-page":"100688","article-title":"A potential therapeutic target: the role of neutrophils in the central nervous system","volume":"33","author":"Salken I","year":"2023","unstructured":"Salken I, Provencio JJ, Coulibaly AP. A potential therapeutic target: the role of neutrophils in the central nervous system. Brain Behav Immun Health. 2023;33:100688. doi:10.1016\/j.bbih.2023.100688"},{"issue":"6","key":"b30","series-title":"Neural Regen Res","first-page":"1764","article-title":"Peripheral blood RNA biomarkers can predict lesion severity in degenerative cervical myelopathy","volume":"20","author":"Zheng Z","year":"2025","unstructured":"Zheng Z, Chen J, Xu J,  Peripheral blood RNA biomarkers can predict lesion severity in degenerative cervical myelopathy. Neural Regen Res. 2025;20(6):1764\u20131775. doi:10.4103\/NRR.NRR-D-23-01069"},{"issue":"2","key":"b31","series-title":"Cell Mol Immunol","first-page":"139","article-title":"SDHA: a key player in T cell-mediated intestinal disease severity","volume":"19","author":"Izquierdo JM","year":"2022","unstructured":"Izquierdo JM. SDHA: a key player in T cell-mediated intestinal disease severity. Cell Mol Immunol. 2022;19(2):139\u2013141. doi:10.1038\/s41423-021-00820-7"},{"issue":"1","key":"b32","series-title":"Am J Med Genet A","first-page":"225","article-title":"SDHA mutation with dominant transmission results in complex II deficiency with ocular, cardiac, and neurologic involvement","volume":"173","author":"Courage C","year":"2017","unstructured":"Courage C, Jackson CB, Hahn D,  SDHA mutation with dominant transmission results in complex II deficiency with ocular, cardiac, and neurologic involvement. Am J Med Genet A. 2017;173(1):225\u2013230. doi:10.1002\/ajmg.a.37986"},{"issue":"11","key":"b33","series-title":"J Neurotrauma","first-page":"946","article-title":"S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury","volume":"30","author":"Goyal A","year":"2013","unstructured":"Goyal A, Failla MD, Niyonkuru C,  S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma. 2013;30(11):946\u2013957. doi:10.1089\/neu.2012.2579"},{"key":"b34","series-title":"Adv Exp Med Biol","first-page":"125","article-title":"Neuron-specific enolase as a biomarker: biochemical and clinical aspects","volume":"867","author":"Isgr\u00f2 MA","year":"2015","unstructured":"Isgr\u00f2 MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125\u2013143. doi:10.1007\/978-94-017-7215-0_9"},{"issue":"11","key":"b35","series-title":"Acta Neurochir (Wien)","first-page":"1439","article-title":"Significance of serial S100b and NSE serum measurements in surgically treated patients with spondylotic cervical myelopathy","volume":"151","author":"Marquardt G","year":"2009","unstructured":"Marquardt G, Setzer M, Szelenyi A, Seifert V, Gerlach R. Significance of serial S100b and NSE serum measurements in surgically treated patients with spondylotic cervical myelopathy. Acta Neurochir (Wien). 2009;151(11):1439\u20131443. doi:10.1007\/s00701-009-0408-0"},{"issue":"10","key":"b36","series-title":"J Clin Neurosci","first-page":"1638","article-title":"Phosphorylated neurofilament subunit levels in the serum of cervical compressive myelopathy patients","volume":"22","author":"Kato S","year":"2015","unstructured":"Kato S, Chikuda H, Ohya J,  Phosphorylated neurofilament subunit levels in the serum of cervical compressive myelopathy patients. J Clin Neurosci. 2015;22(10):1638\u20131642. doi:10.1016\/j.jocn.2015.03.047"},{"issue":"1","key":"b37","series-title":"Neuroscience","first-page":"203","article-title":"Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat","volume":"103","author":"Casha S","year":"2001","unstructured":"Casha S, Yu WR, Fehlings MG. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience. 2001;103(1):203\u2013218. doi:10.1016\/s0306-4522(00)00538-8"},{"issue":"2 suppl","key":"b38","series-title":"J Neurosurg","first-page":"257","article-title":"Presence and significance of CD-95 (Fas\/APO1) expression after spinal cord injury","volume":"94","author":"Zurita M","year":"2001","unstructured":"Zurita M, Vaquero J, Zurita I. Presence and significance of CD-95 (Fas\/APO1) expression after spinal cord injury. J Neurosurg. 2001;94(2 suppl):257\u2013264. doi:10.3171\/spi.2001.94.2.0257"},{"issue":"1","key":"b39","series-title":"Spine (Phila Pa 1976)","first-page":"21","article-title":"Mechanism of destructive pathologic changes in the spinal cord under chronic mechanical compression","volume":"27","author":"Yamaura I","year":"2002","unstructured":"Yamaura I, Yone K, Nakahara S,  Mechanism of destructive pathologic changes in the spinal cord under chronic mechanical compression. Spine (Phila Pa 1976). 2002;27(1):21\u201326. doi:10.1097\/00007632-200201010-00008"},{"key":"b40","series-title":"Front Immunol","first-page":"1070540","article-title":"The role of immune cells and associated immunological factors in the immune response to spinal cord injury","volume":"13","author":"Tang H","year":"2022","unstructured":"Tang H, Gu Y, Jiang L, Zheng G, Pan Z, Jiang X. The role of immune cells and associated immunological factors in the immune response to spinal cord injury. Front Immunol. 2022;13:1070540. doi:10.3389\/fimmu.2022.1070540"},{"issue":"22","key":"b41","series-title":"Int J Mol Sci","first-page":"16385","article-title":"Immune status of individuals with traumatic spinal cord injury: a systematic review and meta-analysis","volume":"24","author":"Valido E","year":"2023","unstructured":"Valido E, Boehl G, Krebs J,  Immune status of individuals with traumatic spinal cord injury: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(22):16385. doi:10.3390\/ijms242216385"},{"issue":"24","key":"b42","series-title":"Int J Mol Sci","first-page":"13577","article-title":"Glial-neuronal interactions in pathogenesis and treatment of spinal cord injury","volume":"22","author":"Lukacova N","year":"2021","unstructured":"Lukacova N, Kisucka A, Kiss Bimbova K,  Glial-neuronal interactions in pathogenesis and treatment of spinal cord injury. Int J Mol Sci. 2021;22(24):13577. doi:10.3390\/ijms222413577"},{"issue":"6","key":"b43","series-title":"Br J Neurosurg","first-page":"776","article-title":"Cost-effectiveness of surgery for degenerative cervical myelopathy in the United Kingdom","volume":"39","author":"Goacher E","year":"2025","unstructured":"Goacher E, Yardanov S, Phillips R,  Cost-effectiveness of surgery for degenerative cervical myelopathy in the United Kingdom. Br J Neurosurg. 2025;39(6):776\u2013780. doi:10.1080\/02688697.2024.2346566"},{"issue":"1","key":"b44","series-title":"Interact J Med Res","first-page":"e36194","article-title":"Existing funding sources in degenerative cervical myelopathy research: scoping review","volume":"11","author":"Bestwick H","year":"2022","unstructured":"Bestwick H, Teh JQ, Mowforth O, Grodzinski B, Kotter M, Davies B. Existing funding sources in degenerative cervical myelopathy research: scoping review. Interact J Med Res. 2022;11(1):e36194. doi:10.2196\/36194"},{"issue":"6","key":"b45","series-title":"Lancet Oncol","first-page":"636","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh SA","year":"2023","unstructured":"McIntosh SA, Alam F, Adams L,  Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol. 2023;24(6):636\u2013645. doi:10.1016\/S1470-2045(23)00182-1"},{"key":"b46","series-title":"Front Endocrinol (Lausanne)","first-page":"330","article-title":"The MAPK pathway-based drug therapeutic targets in pituitary adenomas","volume":"10","author":"Lu M","year":"2019","unstructured":"Lu M, Wang Y, Zhan X. The MAPK pathway-based drug therapeutic targets in pituitary adenomas. Front Endocrinol (Lausanne). 2019;10:330. doi:10.3389\/fendo.2019.00330"},{"issue":"1","key":"b47","series-title":"J Neurosurg Spine","first-page":"93","article-title":"Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model: laboratory investigation","volume":"20","author":"Yamamoto S","year":"2014","unstructured":"Yamamoto S, Kurokawa R, Kim P. Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model: laboratory investigation. J Neurosurg Spine. 2014;20(1):93\u2013101. doi:10.3171\/2013.9.SPINE121136"},{"issue":"23","key":"b48","series-title":"Proc Natl Acad Sci U S A","first-page":"8786","article-title":"The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery","volume":"101","author":"Nikulina E","year":"2004","unstructured":"Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A. 2004;101(23):8786\u20138790. doi:10.1073\/pnas.0402595101"},{"issue":"12","key":"b49","series-title":"EMBO Mol Med","first-page":"1918","article-title":"Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination","volume":"5","author":"Syed YA","year":"2013","unstructured":"Syed YA, Baer A, Hofer MP,  Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. EMBO Mol Med. 2013;5(12):1918\u20131934. doi:10.1002\/emmm.201303123"},{"issue":"7","key":"b50","series-title":"Spine (Phila Pa 1976)","first-page":"827","article-title":"Cervical spondylotic myelopathy: clinicopathologic study on the progression pattern and thin myelinated fibers of the lesions of seven patients examined during complete autopsy","volume":"21","author":"Ito T","year":"1996","unstructured":"Ito T, Oyanagi K, Takahashi H, Takahashi HE, Ikuta F. Cervical spondylotic myelopathy: clinicopathologic study on the progression pattern and thin myelinated fibers of the lesions of seven patients examined during complete autopsy. Spine (Phila Pa 1976). 1996;21(7):827\u2013833. doi:10.1097\/00007632-199604010-00010"},{"issue":"10","key":"b51","series-title":"Nat Med","first-page":"3534","article-title":"Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial","volume":"31","author":"Wick W","year":"2025","unstructured":"Wick W, Lanz LM, Wick A,  Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial. Nat Med. 2025;31(10):3534\u20133541. doi:10.1038\/s41591-025-03928-9"},{"key":"b52","series-title":"Eur J Med Chem","first-page":"115175","article-title":"Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers","volume":"250","author":"Xie Y","year":"2023","unstructured":"Xie Y, Kuang W, Wang D, Yuan K, Yang P. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers. Eur J Med Chem. 2023;250:115175. doi:10.1016\/j.ejmech.2023.115175"},{"issue":"17","key":"b53","series-title":"J Med Chem","first-page":"3984","article-title":"Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2","volume":"50","author":"Moriconi A","year":"2007","unstructured":"Moriconi A, Cesta MC, Cervellera MN,  Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007;50(17):3984\u20134002. doi:10.1021\/jm061469t"},{"issue":"7","key":"b54","series-title":"Arthritis Rheumatol","first-page":"1102","article-title":"The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist","volume":"74","author":"Romano M","year":"2022","unstructured":"Romano M, Arici ZS, Piskin D,  The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Arthritis Rheumatol. 2022;74(7):1102\u20131121. doi:10.1002\/art.42139"},{"issue":"8","key":"b55","series-title":"JAMA Neurol","first-page":"939","article-title":"Anti\u2013tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter I","year":"2018","unstructured":"Peter I, Dubinsky M, Bressman S,  Anti\u2013tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 2018;75(8):939\u2013946. doi:10.1001\/jamaneurol.2018.0605"},{"key":"b56","series-title":"BMC Neurol","first-page":"27","article-title":"Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer\u2019s disease","volume":"8","author":"Tobinick EL","year":"2008","unstructured":"Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer\u2019s disease. BMC Neurol. 2008;8:27. doi:10.1186\/1471-2377-8-27"},{"issue":"5","key":"b57","series-title":"N Engl J Med","first-page":"419","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna A","year":"2017","unstructured":"Khanna A, English SW, Wang XS,  Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419\u2013430. doi:10.1056\/NEJMoa1704154"},{"issue":"2","key":"b58","series-title":"Am J Pathol","first-page":"381","article-title":"Vascular endothelial growth factor-C (VEGF-C\/VEGF-2) promotes angiogenesis in the setting of tissue ischemia","volume":"153","author":"Witzenbichler B","year":"1998","unstructured":"Witzenbichler B, Asahara T, Murohara T,  Vascular endothelial growth factor-C (VEGF-C\/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol. 1998;153(2):381\u2013394. doi:10.1016\/S0002-9440(10)65582-4"},{"issue":"12","key":"b59","series-title":"J Am Soc Nephrol","first-page":"3061","article-title":"Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors","volume":"14","author":"Rizkalla B","year":"2003","unstructured":"Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol. 2003;14(12):3061\u20133071. doi:10.1097\/01.asn.0000099374.58607.c9"},{"issue":"24","key":"b60","series-title":"Proc Natl Acad Sci U S A","first-page":"14389","article-title":"Vascular endothelial growth factor C induces angiogenesis in vivo","volume":"95","author":"Cao Y","year":"1998","unstructured":"Cao Y, Linden P, Farnebo J,  Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1998;95(24):14389\u201314394. doi:10.1073\/pnas.95.24.14389"},{"issue":"6","key":"b1","series-title":"Can J Neurol Sci","first-page":"729","article-title":"Degenerative cervical myelopathy: towards a personalized approach","volume":"49","author":"Hejrati N","year":"2022","unstructured":"Hejrati N, Moghaddamjou A, Marathe N, Fehlings MG. Degenerative cervical myelopathy: towards a personalized approach. Can J Neurol Sci. 2022;49(6):729\u2013740. doi:10.1017\/cjn.2021.214"},{"issue":"2","key":"b2","series-title":"Nat Rev Neurol","first-page":"108","article-title":"Degenerative cervical myelopathy\u2014update and future directions","volume":"16","author":"Badhiwala JH","year":"2020","unstructured":"Badhiwala JH, Ahuja CS, Akbar MA,  Degenerative cervical myelopathy\u2014update and future directions. Nat Rev Neurol. 2020;16(2):108\u2013124. doi:10.1038\/s41582-019-0303-0"},{"issue":"16","key":"b3","series-title":"J Clin Med","first-page":"3626","article-title":"Degenerative cervical myelopathy: clinical presentation, assessment, and natural history","volume":"10","author":"Lannon M","year":"2021","unstructured":"Lannon M, Kachur E. Degenerative cervical myelopathy: clinical presentation, assessment, and natural history. J Clin Med. 2021;10(16):3626. doi:10.3390\/jcm10163626"},{"key":"b4","series-title":"World Neurosurg","first-page":"699","article-title":"Comparing quality of life in cervical spondylotic myelopathy with other chronic debilitating diseases using the Short Form Survey 36-Health Survey","volume":"106","author":"Oh T","year":"2017","unstructured":"Oh T, Lafage R, Lafage V,  Comparing quality of life in cervical spondylotic myelopathy with other chronic debilitating diseases using the Short Form Survey 36-Health Survey. World Neurosurg. 2017;106:699\u2013706. doi:10.1016\/j.wneu.2016.12.124"},{"issue":"5","key":"b5","series-title":"J Neurosurg Spine","first-page":"758","article-title":"Determining the time frame of maximum clinical improvement in surgical decompression for cervical spondylotic myelopathy when stratified by preoperative myelopathy severity: a cervical Quality Outcomes Database study","volume":"37","author":"Berlin C","year":"2022","unstructured":"Berlin C, Marino AC, Mummaneni PV. Determining the time frame of maximum clinical improvement in surgical decompression for cervical spondylotic myelopathy when stratified by preoperative myelopathy severity: a cervical Quality Outcomes Database study. J Neurosurg Spine. 2022;37(5):758\u2013766. doi:10.3171\/2022.5.SPINE211425"},{"issue":"4","key":"b6","series-title":"J Neurosurg Spine","first-page":"453","article-title":"What predicts the best 24-month outcomes following surgery for cervical spondylotic myelopathy? A QOD prospective registry study","volume":"40","author":"Chan AK","year":"2024","unstructured":"Chan AK, Park C, Shaffrey CI,  What predicts the best 24-month outcomes following surgery for cervical spondylotic myelopathy? A QOD prospective registry study. J Neurosurg Spine. 2024;40(4):453\u2013464. doi:10.3171\/2023.11.SPINE23222"},{"issue":"19","key":"b7","series-title":"Spine (Phila Pa 1976)","first-page":"1319","article-title":"Clinical indicators of surgical outcomes in degenerative cervical myelopathy assessed using the JOACMEQ: a prospective multicenter study","volume":"50","author":"Nagoshi N","year":"2025","unstructured":"Nagoshi N, Yamane J, Okubo T,  Clinical indicators of surgical outcomes in degenerative cervical myelopathy assessed using the JOACMEQ: a prospective multicenter study. Spine (Phila Pa 1976). 2025;50(19):1319\u20131326. doi:10.1097\/BRS.0000000000005428"},{"issue":"6","key":"b8","series-title":"Neurosurg Focus","first-page":"E5","article-title":"Which supervised machine learning algorithm can best predict achievement of minimum clinically important difference in neck pain after surgery in patients with cervical myelopathy? A QOD study","volume":"54","author":"Park C","year":"2023","unstructured":"Park C, Mummaneni PV, Gottfried ON,  Which supervised machine learning algorithm can best predict achievement of minimum clinically important difference in neck pain after surgery in patients with cervical myelopathy? A QOD study. Neurosurg Focus. 2023;54(6):E5. doi:10.3171\/2023.3.FOCUS2372"},{"issue":"1","key":"b9","series-title":"Fluids Barriers CNS","first-page":"68","article-title":"Blood-spinal cord barrier disruption in degenerative cervical myelopathy","volume":"20","author":"Kim HW","year":"2023","unstructured":"Kim HW, Yong H, Shea GKH. Blood-spinal cord barrier disruption in degenerative cervical myelopathy. Fluids Barriers CNS. 2023;20(1):68. doi:10.1186\/s12987-023-00463-y"},{"issue":"2","key":"b10","series-title":"Lancet Neurol","first-page":"98","article-title":"Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Fehlings MG","year":"2021","unstructured":"Fehlings MG, Badhiwala JH, Ahn H,  Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Neurol. 2021;20(2):98\u2013106. doi:10.1016\/S1474-4422(20)30407-5"},{"issue":"3","key":"b11","series-title":"BMJ Open","first-page":"e061294","article-title":"Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial\u2014study protocol","volume":"13","author":"Davies B","year":"2023","unstructured":"Davies B, Mowforth OD, Yordanov S,  Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial\u2014study protocol. BMJ Open. 2023;13(3):e061294. doi:10.1136\/bmjopen-2022-061294"},{"key":"b12","article-title":"Finding What Works in Health Care: Standards for Systematic Reviews.","year":"2011","unstructured":"Eden J, Levit L, Berg A, Morton S, eds.Finding What Works in Health Care: Standards for Systematic Reviews. National Academies Press (US);2011. doi:10.17226\/13059"},{"issue":"7","key":"b13","series-title":"PLoS Med","first-page":"e1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J,  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371\/journal.pmed.1000100"},{"issue":"Pt 5","key":"b14","series-title":"Brain","first-page":"1277","article-title":"Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy","volume":"134","author":"Yu WR","year":"2011","unstructured":"Yu WR, Liu T, Kiehl TR, Fehlings MG. Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy. Brain. 2011;134(Pt 5):1277\u20131292. doi:10.1093\/brain\/awr054"},{"issue":"1","key":"b15","series-title":"Sci Rep","first-page":"11873","article-title":"Evidence of impaired macroautophagy in human degenerative cervical myelopathy","volume":"12","author":"Smith SS","year":"2022","unstructured":"Smith SS, Young AMH, Davies BM, Takahashi H, Allinson KSJ, Kotter MRN. Evidence of impaired macroautophagy in human degenerative cervical myelopathy. Sci Rep. 2022;12(1):11873. doi:10.1038\/s41598-022-15158-x"},{"issue":"2","key":"b16","series-title":"Immunity","first-page":"180","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser A","year":"2009","unstructured":"Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180\u2013192. doi:10.1016\/j.immuni.2009.01.001"},{"issue":"5203","key":"b17","series-title":"Science","first-page":"1449","article-title":"The Fas death factor","volume":"267","author":"Nagata S","year":"1995","unstructured":"Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449\u20131456. doi:10.1126\/science.7533326"},{"issue":"3","key":"b18","series-title":"Cell","first-page":"355","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata S","year":"1997","unstructured":"Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355\u2013365. doi:10.1016\/s0092-8674(00)81874-7"},{"issue":"1","key":"b19","series-title":"J Cell Biol","first-page":"15","article-title":"Cell nucleus and DNA fragmentation are not required for apoptosis","volume":"127","author":"Schulze-Osthoff K","year":"1994","unstructured":"Schulze-Osthoff K, Walczak H, Dr\u00f6ge W, Krammer PH. Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol. 1994;127(1):15\u201320. doi:10.1083\/jcb.127.1.15"},{"issue":"1","key":"b20","series-title":"Sci Rep","first-page":"7389","article-title":"Blood spinal cord barrier disruption recovers in patients with degenerative cervical myelopathy after surgical decompression: a prospective cohort study","volume":"13","author":"Schmidt TP","year":"2023","unstructured":"Schmidt TP, J\u00fctten K, Bertram U,  Blood spinal cord barrier disruption recovers in patients with degenerative cervical myelopathy after surgical decompression: a prospective cohort study. Sci Rep. 2023;13(1):7389. doi:10.1038\/s41598-023-34004-2"},{"issue":"2","key":"b21","series-title":"J Spinal Disord Tech","first-page":"145","article-title":"Analysis of interleukin-8, interleukin-10, and tumor necrosis factor-alpha in the cerebrospinal fluid of patients with cervical spondylotic myelopathy","volume":"21","author":"Ito K","year":"2008","unstructured":"Ito K, Matsuyama Y, Yukawa Y, Kato F, Ishiguro N. Analysis of interleukin-8, interleukin-10, and tumor necrosis factor-alpha in the cerebrospinal fluid of patients with cervical spondylotic myelopathy. J Spinal Disord Tech. 2008;21(2):145\u2013147. doi:10.1097\/BSD.0b013e31806458b3"},{"issue":"11","key":"b22","series-title":"Spine J","first-page":"1848","article-title":"Cerebrospinal fluid biomarkers of white matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative cervical spondylotic myelopathy","volume":"22","author":"Tsitsopoulos PP","year":"2022","unstructured":"Tsitsopoulos PP, Mondello S, Holmstr\u00f6m U, Marklund N. Cerebrospinal fluid biomarkers of white matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative cervical spondylotic myelopathy. Spine J. 2022;22(11):1848\u20131856. doi:10.1016\/j.spinee.2022.06.012"},{"issue":"4","key":"b23","series-title":"Arch Neurol","first-page":"553","article-title":"Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions","volume":"57","author":"Cohen O","year":"2000","unstructured":"Cohen O, Biran I, Steiner I. Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions. Arch Neurol. 2000;57(4):553\u2013557. doi:10.1001\/archneur.57.4.553"},{"issue":"1","key":"b24","series-title":"Sci Rep","first-page":"2497","article-title":"Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy","volume":"11","author":"Blume C","year":"2021","unstructured":"Blume C, Geiger MF, M\u00fcller M,  Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy. Sci Rep. 2021;11(1):2497. doi:10.1038\/s41598-021-81766-8"},{"issue":"5 suppl","key":"b25","series-title":"J Periodontol","first-page":"456","article-title":"The role of interleukin-8 in inflammation and mechanisms of regulation","volume":"64","author":"Bickel M","year":"1993","unstructured":"Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol. 1993;64(5 suppl):456\u2013460."},{"key":"b26","series-title":"Front Immunol","first-page":"1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini V","year":"2023","unstructured":"Carlini V, Noonan DM, Abdalalem E,  The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023;14:1161067. doi:10.3389\/fimmu.2023.1161067"},{"issue":"3","key":"b27","series-title":"Microsc Res Tech","first-page":"184","article-title":"TNF\u03b1 and the TNF receptor superfamily: structure-function relationship(s)","volume":"50","author":"Idriss HT","year":"2000","unstructured":"Idriss HT, Naismith JH. TNF\u03b1 and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50(3):184\u2013195. doi:10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H"},{"key":"b28","series-title":"J Neuroinflammation","first-page":"150","article-title":"Neutrophil contribution to spinal cord injury and repair","volume":"11","author":"Neirinckx V","year":"2014","unstructured":"Neirinckx V, Coste C, Franzen R, Gothot A, Rogister B, Wislet S. Neutrophil contribution to spinal cord injury and repair. J Neuroinflammation. 2014;11:150. doi:10.1186\/s12974-014-0150-2"},{"key":"b29","series-title":"Brain Behav Immun Health","first-page":"100688","article-title":"A potential therapeutic target: the role of neutrophils in the central nervous system","volume":"33","author":"Salken I","year":"2023","unstructured":"Salken I, Provencio JJ, Coulibaly AP. A potential therapeutic target: the role of neutrophils in the central nervous system. Brain Behav Immun Health. 2023;33:100688. doi:10.1016\/j.bbih.2023.100688"},{"issue":"6","key":"b30","series-title":"Neural Regen Res","first-page":"1764","article-title":"Peripheral blood RNA biomarkers can predict lesion severity in degenerative cervical myelopathy","volume":"20","author":"Zheng Z","year":"2025","unstructured":"Zheng Z, Chen J, Xu J,  Peripheral blood RNA biomarkers can predict lesion severity in degenerative cervical myelopathy. Neural Regen Res. 2025;20(6):1764\u20131775. doi:10.4103\/NRR.NRR-D-23-01069"},{"issue":"2","key":"b31","series-title":"Cell Mol Immunol","first-page":"139","article-title":"SDHA: a key player in T cell-mediated intestinal disease severity","volume":"19","author":"Izquierdo JM","year":"2022","unstructured":"Izquierdo JM. SDHA: a key player in T cell-mediated intestinal disease severity. Cell Mol Immunol. 2022;19(2):139\u2013141. doi:10.1038\/s41423-021-00820-7"},{"issue":"1","key":"b32","series-title":"Am J Med Genet A","first-page":"225","article-title":"SDHA mutation with dominant transmission results in complex II deficiency with ocular, cardiac, and neurologic involvement","volume":"173","author":"Courage C","year":"2017","unstructured":"Courage C, Jackson CB, Hahn D,  SDHA mutation with dominant transmission results in complex II deficiency with ocular, cardiac, and neurologic involvement. Am J Med Genet A. 2017;173(1):225\u2013230. doi:10.1002\/ajmg.a.37986"},{"issue":"11","key":"b33","series-title":"J Neurotrauma","first-page":"946","article-title":"S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury","volume":"30","author":"Goyal A","year":"2013","unstructured":"Goyal A, Failla MD, Niyonkuru C,  S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma. 2013;30(11):946\u2013957. doi:10.1089\/neu.2012.2579"},{"key":"b34","series-title":"Adv Exp Med Biol","first-page":"125","article-title":"Neuron-specific enolase as a biomarker: biochemical and clinical aspects","volume":"867","author":"Isgr\u00f2 MA","year":"2015","unstructured":"Isgr\u00f2 MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125\u2013143. doi:10.1007\/978-94-017-7215-0_9"},{"issue":"11","key":"b35","series-title":"Acta Neurochir (Wien)","first-page":"1439","article-title":"Significance of serial S100b and NSE serum measurements in surgically treated patients with spondylotic cervical myelopathy","volume":"151","author":"Marquardt G","year":"2009","unstructured":"Marquardt G, Setzer M, Szelenyi A, Seifert V, Gerlach R. Significance of serial S100b and NSE serum measurements in surgically treated patients with spondylotic cervical myelopathy. Acta Neurochir (Wien). 2009;151(11):1439\u20131443. doi:10.1007\/s00701-009-0408-0"},{"issue":"10","key":"b36","series-title":"J Clin Neurosci","first-page":"1638","article-title":"Phosphorylated neurofilament subunit levels in the serum of cervical compressive myelopathy patients","volume":"22","author":"Kato S","year":"2015","unstructured":"Kato S, Chikuda H, Ohya J,  Phosphorylated neurofilament subunit levels in the serum of cervical compressive myelopathy patients. J Clin Neurosci. 2015;22(10):1638\u20131642. doi:10.1016\/j.jocn.2015.03.047"},{"issue":"1","key":"b37","series-title":"Neuroscience","first-page":"203","article-title":"Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat","volume":"103","author":"Casha S","year":"2001","unstructured":"Casha S, Yu WR, Fehlings MG. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience. 2001;103(1):203\u2013218. doi:10.1016\/s0306-4522(00)00538-8"},{"issue":"2 suppl","key":"b38","series-title":"J Neurosurg","first-page":"257","article-title":"Presence and significance of CD-95 (Fas\/APO1) expression after spinal cord injury","volume":"94","author":"Zurita M","year":"2001","unstructured":"Zurita M, Vaquero J, Zurita I. Presence and significance of CD-95 (Fas\/APO1) expression after spinal cord injury. J Neurosurg. 2001;94(2 suppl):257\u2013264. doi:10.3171\/spi.2001.94.2.0257"},{"issue":"1","key":"b39","series-title":"Spine (Phila Pa 1976)","first-page":"21","article-title":"Mechanism of destructive pathologic changes in the spinal cord under chronic mechanical compression","volume":"27","author":"Yamaura I","year":"2002","unstructured":"Yamaura I, Yone K, Nakahara S,  Mechanism of destructive pathologic changes in the spinal cord under chronic mechanical compression. Spine (Phila Pa 1976). 2002;27(1):21\u201326. doi:10.1097\/00007632-200201010-00008"},{"key":"b40","series-title":"Front Immunol","first-page":"1070540","article-title":"The role of immune cells and associated immunological factors in the immune response to spinal cord injury","volume":"13","author":"Tang H","year":"2022","unstructured":"Tang H, Gu Y, Jiang L, Zheng G, Pan Z, Jiang X. The role of immune cells and associated immunological factors in the immune response to spinal cord injury. Front Immunol. 2022;13:1070540. doi:10.3389\/fimmu.2022.1070540"},{"issue":"22","key":"b41","series-title":"Int J Mol Sci","first-page":"16385","article-title":"Immune status of individuals with traumatic spinal cord injury: a systematic review and meta-analysis","volume":"24","author":"Valido E","year":"2023","unstructured":"Valido E, Boehl G, Krebs J,  Immune status of individuals with traumatic spinal cord injury: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(22):16385. doi:10.3390\/ijms242216385"},{"issue":"24","key":"b42","series-title":"Int J Mol Sci","first-page":"13577","article-title":"Glial-neuronal interactions in pathogenesis and treatment of spinal cord injury","volume":"22","author":"Lukacova N","year":"2021","unstructured":"Lukacova N, Kisucka A, Kiss Bimbova K,  Glial-neuronal interactions in pathogenesis and treatment of spinal cord injury. Int J Mol Sci. 2021;22(24):13577. doi:10.3390\/ijms222413577"},{"issue":"6","key":"b43","series-title":"Br J Neurosurg","first-page":"776","article-title":"Cost-effectiveness of surgery for degenerative cervical myelopathy in the United Kingdom","volume":"39","author":"Goacher E","year":"2025","unstructured":"Goacher E, Yardanov S, Phillips R,  Cost-effectiveness of surgery for degenerative cervical myelopathy in the United Kingdom. Br J Neurosurg. 2025;39(6):776\u2013780. doi:10.1080\/02688697.2024.2346566"},{"issue":"1","key":"b44","series-title":"Interact J Med Res","first-page":"e36194","article-title":"Existing funding sources in degenerative cervical myelopathy research: scoping review","volume":"11","author":"Bestwick H","year":"2022","unstructured":"Bestwick H, Teh JQ, Mowforth O, Grodzinski B, Kotter M, Davies B. Existing funding sources in degenerative cervical myelopathy research: scoping review. Interact J Med Res. 2022;11(1):e36194. doi:10.2196\/36194"},{"issue":"6","key":"b45","series-title":"Lancet Oncol","first-page":"636","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh SA","year":"2023","unstructured":"McIntosh SA, Alam F, Adams L,  Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol. 2023;24(6):636\u2013645. doi:10.1016\/S1470-2045(23)00182-1"},{"key":"b46","series-title":"Front Endocrinol (Lausanne)","first-page":"330","article-title":"The MAPK pathway-based drug therapeutic targets in pituitary adenomas","volume":"10","author":"Lu M","year":"2019","unstructured":"Lu M, Wang Y, Zhan X. The MAPK pathway-based drug therapeutic targets in pituitary adenomas. Front Endocrinol (Lausanne). 2019;10:330. doi:10.3389\/fendo.2019.00330"},{"issue":"1","key":"b47","series-title":"J Neurosurg Spine","first-page":"93","article-title":"Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model: laboratory investigation","volume":"20","author":"Yamamoto S","year":"2014","unstructured":"Yamamoto S, Kurokawa R, Kim P. Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model: laboratory investigation. J Neurosurg Spine. 2014;20(1):93\u2013101. doi:10.3171\/2013.9.SPINE121136"},{"issue":"23","key":"b48","series-title":"Proc Natl Acad Sci U S A","first-page":"8786","article-title":"The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery","volume":"101","author":"Nikulina E","year":"2004","unstructured":"Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A. 2004;101(23):8786\u20138790. doi:10.1073\/pnas.0402595101"},{"issue":"12","key":"b49","series-title":"EMBO Mol Med","first-page":"1918","article-title":"Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination","volume":"5","author":"Syed YA","year":"2013","unstructured":"Syed YA, Baer A, Hofer MP,  Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. EMBO Mol Med. 2013;5(12):1918\u20131934. doi:10.1002\/emmm.201303123"},{"issue":"7","key":"b50","series-title":"Spine (Phila Pa 1976)","first-page":"827","article-title":"Cervical spondylotic myelopathy: clinicopathologic study on the progression pattern and thin myelinated fibers of the lesions of seven patients examined during complete autopsy","volume":"21","author":"Ito T","year":"1996","unstructured":"Ito T, Oyanagi K, Takahashi H, Takahashi HE, Ikuta F. Cervical spondylotic myelopathy: clinicopathologic study on the progression pattern and thin myelinated fibers of the lesions of seven patients examined during complete autopsy. Spine (Phila Pa 1976). 1996;21(7):827\u2013833. doi:10.1097\/00007632-199604010-00010"},{"issue":"10","key":"b51","series-title":"Nat Med","first-page":"3534","article-title":"Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial","volume":"31","author":"Wick W","year":"2025","unstructured":"Wick W, Lanz LM, Wick A,  Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial. Nat Med. 2025;31(10):3534\u20133541. doi:10.1038\/s41591-025-03928-9"},{"key":"b52","series-title":"Eur J Med Chem","first-page":"115175","article-title":"Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers","volume":"250","author":"Xie Y","year":"2023","unstructured":"Xie Y, Kuang W, Wang D, Yuan K, Yang P. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers. Eur J Med Chem. 2023;250:115175. doi:10.1016\/j.ejmech.2023.115175"},{"issue":"17","key":"b53","series-title":"J Med Chem","first-page":"3984","article-title":"Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2","volume":"50","author":"Moriconi A","year":"2007","unstructured":"Moriconi A, Cesta MC, Cervellera MN,  Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007;50(17):3984\u20134002. doi:10.1021\/jm061469t"},{"issue":"7","key":"b54","series-title":"Arthritis Rheumatol","first-page":"1102","article-title":"The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist","volume":"74","author":"Romano M","year":"2022","unstructured":"Romano M, Arici ZS, Piskin D,  The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Arthritis Rheumatol. 2022;74(7):1102\u20131121. doi:10.1002\/art.42139"},{"issue":"8","key":"b55","series-title":"JAMA Neurol","first-page":"939","article-title":"Anti\u2013tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter I","year":"2018","unstructured":"Peter I, Dubinsky M, Bressman S,  Anti\u2013tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 2018;75(8):939\u2013946. doi:10.1001\/jamaneurol.2018.0605"},{"key":"b56","series-title":"BMC Neurol","first-page":"27","article-title":"Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer\u2019s disease","volume":"8","author":"Tobinick EL","year":"2008","unstructured":"Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer\u2019s disease. BMC Neurol. 2008;8:27. doi:10.1186\/1471-2377-8-27"},{"issue":"5","key":"b57","series-title":"N Engl J Med","first-page":"419","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna A","year":"2017","unstructured":"Khanna A, English SW, Wang XS,  Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419\u2013430. doi:10.1056\/NEJMoa1704154"},{"issue":"2","key":"b58","series-title":"Am J Pathol","first-page":"381","article-title":"Vascular endothelial growth factor-C (VEGF-C\/VEGF-2) promotes angiogenesis in the setting of tissue ischemia","volume":"153","author":"Witzenbichler B","year":"1998","unstructured":"Witzenbichler B, Asahara T, Murohara T,  Vascular endothelial growth factor-C (VEGF-C\/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol. 1998;153(2):381\u2013394. doi:10.1016\/S0002-9440(10)65582-4"},{"issue":"12","key":"b59","series-title":"J Am Soc Nephrol","first-page":"3061","article-title":"Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors","volume":"14","author":"Rizkalla B","year":"2003","unstructured":"Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol. 2003;14(12):3061\u20133071. doi:10.1097\/01.asn.0000099374.58607.c9"},{"issue":"24","key":"b60","series-title":"Proc Natl Acad Sci U S A","first-page":"14389","article-title":"Vascular endothelial growth factor C induces angiogenesis in vivo","volume":"95","author":"Cao Y","year":"1998","unstructured":"Cao Y, Linden P, Farnebo J,  Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1998;95(24):14389\u201314394. doi:10.1073\/pnas.95.24.14389"}],"container-title":["Journal of Neurosurgery: Spine"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-spine\/aop\/article-10.3171-2025.12.SPINE251122\/article-10.3171-2025.12.SPINE251122.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-spine\/aop\/article-10.3171-2025.12.SPINE251122\/article-10.3171-2025.12.SPINE251122.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-spine\/aop\/article-10.3171-2025.12.SPINE251122\/article-10.3171-2025.12.SPINE251122.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:39:25Z","timestamp":1779359965000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-spine\/aop\/article-10.3171-2025.12.SPINE251122\/article-10.3171-2025.12.SPINE251122.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":120,"URL":"https:\/\/doi.org\/10.3171\/2025.12.spine251122","relation":{},"ISSN":["1547-5654"],"issn-type":[{"value":"1547-5654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}